# Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes

> **NCT01011868** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 494 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** BI 10773 placebo
- **DRUG:** BI 10773 low dose
- **DRUG:** BI 10773 high dose
- **DRUG:** BI 10773 placebo

## Key facts

- **NCT ID:** NCT01011868
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2012-05
- **Final completion:** —
- **Target enrollment:** 494 (ACTUAL)
- **Last updated:** 2014-09-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01011868

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01011868, "Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01011868. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*